

# Massimiliano Fabbiani

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3038709/publications.pdf>

Version: 2024-02-01

105  
papers

2,346  
citations

201674

27  
h-index

254184

43  
g-index

109  
all docs

109  
docs citations

109  
times ranked

4472  
citing authors

#	ARTICLE	IF	CITATIONS
1	Real-Life Impact of Drug Toxicity on Dolutegravir Tolerability: Clinical Practice Data from a Multicenter Italian Cohort. <i>Viruses</i> , 2022, 14, 163.	3.3	5
2	Effectiveness of integrase strand transfer inhibitors in HIV-infected treatment-experienced individuals across Europe. <i>HIV Medicine</i> , 2022, , .	2.2	5
3	Discordant Liver Fibrosis Predictors in Virologically Suppressed People Living with HIV without Hepatitis Virus Infection. <i>Diagnostics</i> , 2022, 12, 14.	2.6	3
4	High rates of sustained virological response despite premature discontinuation of directly acting antivirals in HCV-infected patients treated in a real-life setting. <i>Journal of Viral Hepatitis</i> , 2021, 28, 558-568.	2.0	3
5	Integrase Inhibitors Use and Cytomegalovirus Infection Predict Immune Recovery in People Living With HIV Starting First-Line Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 86, 119-127.	2.1	15
6	Nucleoside Reverse-Transcriptase Inhibitor Resistance Mutations Predict Virological Failure in Human Immunodeficiency Virus-Positive Patients During Lamivudine Plus Dolutegravir Maintenance Therapy in Clinical Practice. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab103.	0.9	8
7	Extremely potent human monoclonal antibodies from COVID-19 convalescent patients. <i>Cell</i> , 2021, 184, 1821-1835.e16.	28.9	180
8	Predictors of starting antimicrobial treatment in patients with nontuberculous mycobacterial lung disease in the Italian scenario: A SITA GIOVANI-IRENE promoted web-survey. <i>Respiratory Medicine</i> , 2021, 179, 106341.	2.9	2
9	Seroprevalence of SARS-CoV-2 Antibodies in HIV-Infected Patients in Rome, Italy during the COVID-19 Outbreak. <i>Diagnostics</i> , 2021, 11, 1154.	2.6	9
10	Efficacy and durability of two- vs. three-drug integrase inhibitor-based regimens in virologically suppressed HIV-infected patients: Data from real-life ODOACRE cohort. <i>HIV Medicine</i> , 2021, 22, 843-853.	2.2	18
11	Effectiveness of integrase strand transfer inhibitor-based regimens in HIV-infected treatment-naïve individuals: results from a European multi-cohort study. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2394-2399.	3.0	6
12	Antimicrobial Stewardship: From Bedside to Theory. Thirteen Examples of Old and More Recent Strategies from Everyday Clinical Practice. <i>Antibiotics</i> , 2020, 9, 398.	3.7	5
13	Fosfomycin as Partner Drug for Systemic Infection Management. A Systematic Review of Its Synergistic Properties from In Vitro and In Vivo Studies. <i>Antibiotics</i> , 2020, 9, 500.	3.7	38
14	The Model for Early COVID-19 Recognition (MECOR) Score: A Proof-of-Concept for a Simple and Low-Cost Tool to Recognize a Possible Viral Etiology in Community-Acquired Pneumonia Patients during COVID-19 Outbreak. <i>Diagnostics</i> , 2020, 10, 619.	2.6	33
15	The University of California San Diego performance-based skills assessment: a useful tool to detect mild everyday functioning difficulties in HIV-infected patients with very good immunological condition. <i>Journal of NeuroVirology</i> , 2020, 26, 899-907.	2.1	1
16	Evolution of cellular HIV DNA levels in virologically suppressed patients switching to dolutegravir/lamivudine versus maintaining a triple regimen: a prospective, longitudinal, matched, controlled study. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1599-1603.	3.0	10
17	Pharmacokinetic profile of dolutegravir after transjugular intrahepatic portosystemic shunt placement. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1354-1356.	3.0	1
18	Enhanced Immunological Recovery With Early Start of Antiretroviral Therapy During Acute or Early HIV Infection—Results of Italian Network of ACuTe HIV InfectiON (INACTiON) Retrospective Study. <i>Pathogens and Immunity</i> , 2020, 5, 8.	3.1	16

#	ARTICLE	IF	CITATIONS
19	Hepatitis C virus-related factors associated WITH cognitive performance in HIV-HCV-coinfected patients. <i>Journal of NeuroVirology</i> , 2019, 25, 866-873.	2.1	8
20	Reduced soluble CD14 levels after switching from a dual regimen with lamivudine plus boosted protease inhibitors to lamivudine plus dolutegravir in virologically suppressed HIV-infected patients. <i>HIV Research and Clinical Practice</i> , 2019, 20, 92-98.	1.1	10
21	Liver fibrosis is associated with cognitive impairment in people living with HIV. <i>Infection</i> , 2019, 47, 589-593.	4.7	4
22	3-Year Efficacy and Durability of Simplification to Single Tablet Regimens: A Comparison between Co-Formulated Efavirenz/Emtricitabine/Tenofovir and Rilpivirine/Emtricitabine/Tenofovir. <i>Antiviral Therapy</i> , 2018, 23, 139-148.	1.0	9
23	Higher Levels of Peripheral Th17 T CD4+ Cells Are Associated With Immunological Non Response in HIV-Infected Patients Under Effective ART. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 77, e45-e47.	2.1	2
24	Reply. <i>Hepatology</i> , 2018, 67, 1182-1183.	7.3	0
25	Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 1955-1964.	3.0	29
26	The NLRP3 Inflammasome Is Upregulated in HIV-Infected Antiretroviral Therapy-Treated Individuals with Defective Immune Recovery. <i>Frontiers in Immunology</i> , 2018, 9, 214.	4.8	71
27	Cohort Profile: Standardized Management of Antiretroviral Therapy Cohort (MASTER Cohort). <i>International Journal of Epidemiology</i> , 2017, 46, dyv192.	1.9	15
28	Verbal list learning and memory profiles in HIV-infected adults, Alzheimer's disease, and Parkinson's disease: An evaluation of the hippocampal hypothesis of NeuroAIDS. <i>Applied Neuropsychology Adult</i> , 2017, 24, 410-419.	1.2	11
29	Evolution of blood-associated HIV-1 DNA levels after 48 weeks of switching to atazanavir/ritonavir+lamivudine dual therapy versus continuing triple therapy in the randomized AtLaS-M trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2055-2059.	3.0	28
30	Unexpected viral relapses in hepatitis C virus-infected patients diagnosed with hepatocellular carcinoma during treatment with direct-acting antivirals. <i>Hepatology</i> , 2017, 66, 992-994.	7.3	15
31	Lipid-lowering effect and changes in estimated cardiovascular risk after switching to a tenofovir-containing regimen for the treatment of HIV-infected patients. <i>Journal of Chemotherapy</i> , 2017, 29, 299-307.	1.5	5
32	Reply. <i>Hepatology</i> , 2017, 66, 2091-2092.	7.3	1
33	Brief Report: Peripheral Monocyte/Macrophage Phenotypes Associated With the Evolution of Cognitive Performance in HIV-Infected Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 76, 219-224.	2.1	16
34	Update of the budget impact analysis of the simplification to atazanavir + ritonavir + lamivudine dual therapy of HIV-positive patients receiving atazanavir-based triple therapies in Italy starting from data of the Atlas-M trial. <i>ClinicoEconomics and Outcomes Research</i> , 2017, Volume 9, 569-571.	1.9	3
35	Budget impact analysis of the simplification to atazanavir + ritonavir + lamivudine dual therapy of HIV-positive patients receiving atazanavir-based triple therapies in Italy starting from data of the Atlas-M trial. <i>ClinicoEconomics and Outcomes Research</i> , 2017, Volume 9, 173-179.	1.9	9
36	Treatment simplification to atazanavir/ritonavir+lamivudine versus maintenance of atazanavir/ritonavir+two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M). <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, dkw557.	3.0	62

#	ARTICLE	IF	CITATIONS
37	Immunogenicity and Safety of the 13-Valent Pneumococcal Conjugate Vaccine versus the 23-Valent Polysaccharide Vaccine in Unvaccinated HIV-Infected Adults: A Pilot, Prospective Controlled Study. PLoS ONE, 2016, 11, e0156523.	2.5	21
38	Reduced risk of Efavirenz Discontinuation in Na <sup>+</sup> -ve Patients Starting First-Line Antiretroviral Therapy with Single Tablet versus dual Tablet Regimen. HIV Medicine, 2016, 17, 385-389.	2.2	3
39	Neuropsychological screening tools in Italian HIV+ patients: a comparison of Montreal Cognitive Assessment (MoCA) and Mini Mental State Examination (MMSE). Clinical Neuropsychologist, 2016, 30, 1457-1468.	2.3	19
40	Virological control and metabolic improvement in HIV-infected, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy: Table 1. Journal of Antimicrobial Chemotherapy, 2016, 71, 2359-2361.	3.0	22
41	Impact of 48 weeks of atazanavir/ritonavir plus lamivudine dual therapy on cellular HIV-DNA levels in the AtLaS pilot study. Journal of Antimicrobial Chemotherapy, 2016, 71, 3621-3622.	3.0	3
42	Simplification to a dual regimen with darunavir/ritonavir plus lamivudine or emtricitabine in virologically-suppressed HIV-infected patients. Journal of Infection, 2016, 73, 619-623.	3.3	11
43	Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: a multicenter observational study. BMC Infectious Diseases, 2016, 16, 401.	2.9	6
44	Liver fibrosis progression and clinical outcomes are intertwined. Medicine (United States), 2016, 95, e4091.	1.0	17
45	Initial antifungal strategy does not correlate with mortality in patients with candidemia. European Journal of Clinical Microbiology and Infectious Diseases, 2016, 35, 187-193.	2.9	22
46	Relationship between self-reported adherence, antiretroviral drug concentration measurement and self-reported symptoms in patients treated for HIV-1 infection. Infectious Diseases, 2016, 48, 48-55.	2.8	5
47	Cognitive reserve and neuropsychological functioning in older HIV-infected people. Journal of NeuroVirology, 2016, 22, 575-583.	2.1	33
48	Evaluation and Optimization of an ELISA Procedure to Quantify Antibodies Against Pneumococcal Polysaccharides Included in the 13-Valent Conjugate Vaccine. Journal of Immunoassay and Immunochemistry, 2016, 37, 189-200.	1.1	5
49	Baseline CD4 <sup>+</sup> T-cell Count and Cardiovascular Risk Factors Predict the Evolution of Cognitive Performance During 2-Year follow-up in HIV-Infected Patients. Antiviral Therapy, 2015, 20, 433-440.	1.0	11
50	Antiretroviral Neuropenetrations Better Correlate with Cognitive Performance of HIV-Infected Patients after Accounting for drug Susceptibility. Antiviral Therapy, 2015, 20, 441-447.	1.0	34
51	Risk of Severe Non AIDS Events Is Increased among Patients Unable to Increase their CD4+ T-Cell Counts >200/ $\mu$ l Despite Effective HAART. PLoS ONE, 2015, 10, e0124741.	2.5	36
52	Resource-saving advice from an infectious diseases specialist team in a large university hospital: an exportable model?. Future Microbiology, 2015, 10, 15-20.	2.0	8
53	Efficacy and safety of treatment simplification to atazanavir/ritonavir+lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study. Journal of Antimicrobial Chemotherapy, 2015, 70, 1843-1849.	3.0	38
54	Cancer incidence and mortality for all causes in HIV-infected patients over a quarter century: a multicentre cohort study. BMC Public Health, 2015, 15, 235.	2.9	29

#	ARTICLE	IF	CITATIONS
55	Two Distinct Hepatitis C Virus Genotype 1a Clades Have Different Geographical Distribution and Association With Natural Resistance to NS3 Protease Inhibitors. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofv043.	0.9	30
56	Survival in HIV-Infected Patients after a Cancer Diagnosis in the cART Era: Results of an Italian Multicenter Study. <i>PLoS ONE</i> , 2014, 9, e94768.	2.5	50
57	Liver fibrosis is associated with cognitive impairment in HIV-positive patients. <i>Journal of the International AIDS Society</i> , 2014, 17, 19722.	3.0	5
58	Simplification to co-formulated rilpivirine/emtricitabine/tenofovir in virologically suppressed patients: Data from a multicenter cohort. <i>Journal of the International AIDS Society</i> , 2014, 17, 19812.	3.0	17
59	Simplification to atazanavir/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trial. <i>Journal of the International AIDS Society</i> , 2014, 17, 19808.	3.0	13
60	Prevalence of osteoporosis and predictors of low BMD in a cohort of HIV-1-infected patients in Rome: features of a population at high risk. <i>Journal of the International AIDS Society</i> , 2014, 17, 19570.	3.0	1
61	Switching to lamivudine plus darunavir/r dual therapy in a cohort of treatment-experienced HIV-positive patients: the experience of an Italian centre. <i>Journal of the International AIDS Society</i> , 2014, 17, 19817.	3.0	7
62	Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: a multicenter analysis. <i>Journal of the International AIDS Society</i> , 2014, 17, 19802.	3.0	2
63	Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study). <i>Scandinavian Journal of Infectious Diseases</i> , 2014, 46, 34-45.	1.5	23
64	Immune response to influenza A(H1N1)v in HIV-infected patients. <i>Journal of Infection in Developing Countries</i> , 2014, 8, 101-109.	1.2	4
65	Pharmacokinetics of etravirine in HIV-infected patients concomitantly treated with rifampin for tuberculosis. <i>Infection</i> , 2014, 42, 775-8.	4.7	6
66	Single tablet regimens are associated with reduced Efavirenz withdrawal in antiretroviral therapy naïve or switching for simplification HIV-infected patients. <i>BMC Infectious Diseases</i> , 2014, 14, 26.	2.9	17
67	Detection of <i>HLA-B*57:01</i> by real-time PCR: implementation into routine clinical practice and additional validation data. <i>Pharmacogenomics</i> , 2014, 15, 319-327.	1.3	17
68	Ophthalmic artery resistance index is increased in HIV-Infected patients and is influenced by protease inhibitors exposure. <i>Journal of Infection</i> , 2014, 68, 500-503.	3.3	1
69	Atazanavir-Induced Severe Episodes of Kidney Stones in an HIV-1-Infected Subject Characterized by a CYP3A Poor Metabolizer Phenotype. <i>British Journal of Pharmaceutical Research</i> , 2014, 4, 2594-2598.	0.4	0
70	Comparison of cognitive performance in HIV or HCV mono-infected and HIV-HCV co-infected patients. <i>Infection</i> , 2013, 41, 1103-1109.	4.7	35
71	Evaluation of emotion processing in HIV-infected patients and correlation with cognitive performance. <i>BMC Psychology</i> , 2013, 1, 3.	2.1	11
72	Combining social and genetic networks to study HIV transmission in mixing risk groups. <i>European Physical Journal: Special Topics</i> , 2013, 222, 1377-1387.	2.6	7

#	ARTICLE	IF	CITATIONS
73	Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment) Tj ETQq1 1 0.784314 rgBT /Overlock 10 T 5	3.0	15
74	Cardiovascular risk factors and carotid intima-media thickness are associated with lower cognitive performance in HIV-infected patients. HIV Medicine, 2013, 14, 136-144.	2.2	77
75	HIV-infected patients show impaired cellular immune response to influenza vaccination compared to healthy subjects. Vaccine, 2013, 31, 2914-2918.	3.8	12
76	Variability of Raltegravir Plasma Levels in the Clinical Setting. Pharmacology, 2013, 92, 43-48.	2.2	9
77	Validation of an UPLC-MS/MS Method for Quantitative Analysis of Raltegravir in Human Plasma Samples. Therapeutic Drug Monitoring, 2013, 35, 258-263.	2.0	9
78	Revised Central Nervous System Neuropenetration-Effectiveness Score is Associated with Cognitive Disorders in HIV-Infected Patients with Controlled Plasma Viraemia. Antiviral Therapy, 2013, 18, 153-160.	1.0	52
79	Is There a Drug-Drug Interaction Between Darunavir/Ritonavir and Raltegravir?. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 60, e18-e20.	2.1	3
80	Factors influencing the normalization of CD4+ T-cell count, percentage and CD4+/CD8+ T-cell ratio in HIV-infected patients on long-term suppressive antiretroviral therapy. Clinical Microbiology and Infection, 2012, 18, 449-458.	6.0	61
81	Coccidioidomycosis of cervical lymph nodes in an HIV-infected patient with immunologic reconstitution on potent HAART: a rare observation in a nonendemic area. Diagnostic Microbiology and Infectious Disease, 2012, 72, 185-187.	1.8	19
82	Predictors of first-line antiretroviral therapy discontinuation due to drug-related adverse events in HIV-infected patients: a retrospective cohort study. BMC Infectious Diseases, 2012, 12, 296.	2.9	73
83	Virological effectiveness and CD4+ T-cell increase over early and late courses in HIV infected patients on antiretroviral therapy: focus on HCV and anchor class received. AIDS Research and Therapy, 2012, 9, 18.	1.7	11
84	Effect of Aging and Human Immunodeficiency Virus Infection on Cognitive Abilities. Journal of the American Geriatrics Society, 2012, 60, 2048-2055.	2.6	30
85	Increased ophthalmic artery resistance index is associated with cognitive impairment in HIV-infected patients. Journal of Infection, 2012, 65, 439-446.	3.3	16
86	Mitochondrial DNA haplogroups and incidence of lipodystrophy in HIV-infected patients on long-term antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, , 1.	2.1	3
87	Darunavir/ritonavir and raltegravir coadministered in routine clinical practice: Potential role for an unexpected drug interaction. Pharmacological Research, 2011, 63, 249-253.	7.1	23
88	Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients. Vaccine, 2011, 29, 2836-2839.	3.8	29
89	Update on emergence of HIV-1 resistance to antiretroviral drug classes in an Italian national database: 2007-2009. Clinical Microbiology and Infection, 2011, 17, 1352-1355.	6.0	6
90	Clinical presentation, microbiological features and correlates of disease severity of 2009 pandemic influenza A (H1N1) infection. European Journal of Clinical Microbiology and Infectious Diseases, 2011, 30, 541-549.	2.9	11

#	ARTICLE	IF	CITATIONS
91	Relationship between antiretroviral plasma concentration and emergence of HIV-1 resistance mutations at treatment failure. <i>Infection</i> , 2011, 39, 563-569.	4.7	13
92	Prospective evaluation of epidemiological, clinical, and microbiological features of pandemic influenza A (H1N1) virus infection in Italy. <i>Journal of Medical Virology</i> , 2011, 83, 2057-2065.	5.0	11
93	Tenofovir discontinuation could predispose to urolithiasis in atazanavir-treated patients. <i>Journal of Infection</i> , 2011, 62, 319-321.	3.3	13
94	The Effect of Polymorphisms in Candidate Genes on the Long-Term Risk of Lipodystrophy and Dyslipidemia in HIV-Infected White Patients Starting Antiretroviral Therapy. <i>AIDS Research and Human Retroviruses</i> , 2011, 27, 1299-1309.	1.1	16
95	Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients. <i>Neurology</i> , 2011, 76, 1403-1409.	1.1	217
96	Lipid-lowering effect of tenofovir in HIV-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 682-683.	3.0	24
97	Comparative determination of HIV-1 co-receptor tropism by Enhanced Sensitivity Trofile, gp120 V3-loop RNA and DNA genotyping. <i>Retrovirology</i> , 2010, 7, 56.	2.0	50
98	Mid-dosing interval concentration of atazanavir and virological outcome in patients treated for HIV-1 infection. <i>HIV Medicine</i> , 2010, 11, 326-333.	2.2	20
99	Comparison of HIV-1 Genotypic Resistance Test Interpretation Systems in Predicting Virological Outcomes Over Time. <i>PLoS ONE</i> , 2010, 5, e11505.	2.5	56
100	The Threshold Bootstrap Clustering: A New Approach to Find Families or Transmission Clusters within Molecular Quasispecies. <i>PLoS ONE</i> , 2010, 5, e13619.	2.5	15
101	Asymmetry of the Regimen Is Correlated to Self-Reported Suboptimal Adherence: Results From AdUCSC, a Cohort Study on Adherence in Italy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010, 55, 411-412.	2.1	11
102	Pharmacokinetic variability of antiretroviral drugs and correlation with virological outcome: 2 years of experience in routine clinical practice. <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 64, 109-117.	3.0	71
103	Epidemiological and clinical study of viral respiratory tract infections in children from Italy. <i>Journal of Medical Virology</i> , 2009, 81, 750-756.	5.0	67
104	Impact of Hepatitis B Vaccination in Children Born to HBsAg-Positive Mothers: a 20-year Retrospective Study. <i>Infection</i> , 2009, 37, 340-343.	4.7	18
105	Human bocavirus detection in an atopic child affected by pneumonia associated with wheezing. <i>Journal of Clinical Virology</i> , 2007, 40, 43-45.	3.1	16